In these studies, patients receiving SGLT2 inhibitors had lower rates of moderate-to-severe hyperkalemia compared to placebo, despite the concomitant use of RAASi and mineralocorticoid receptor antagonists (MRAs) [2,3,5,24]. The gene discussed is NR3C2; the disease is Hyperkalemia.